8/12/2019 HPL Pharma Ppt (1)
1/70
1
8/12/2019 HPL Pharma Ppt (1)
2/70
Name Roll no
Samiksha Dike 11
Abdul Samad 01 Furqan Ahmed 13
Dipali Manjucha 27
Javed Khan 17
2
GROUP MEMBERS
8/12/2019 HPL Pharma Ppt (1)
3/70
PHARMACEUTICAL INDUSTRY
LUPIN PHARMACEUTICALS
PFIZER PHARMACEUTICALS
1
2
3
TOPICS
8/12/2019 HPL Pharma Ppt (1)
4/70
The Pharmaceutical Industry
4
8/12/2019 HPL Pharma Ppt (1)
5/70
OVERVIEW
5
Mission
Value
8/12/2019 HPL Pharma Ppt (1)
6/70
6
Formulations
Pharmaceuticals
API
8/12/2019 HPL Pharma Ppt (1)
7/70
Top Companies in World
7
8/12/2019 HPL Pharma Ppt (1)
8/70
8
22,476
26,475
33,547
35,645
37,020
42,813
44,200
45,987
53,324
67,809
0 20,000 40,000 60,000 80,000
Abott laboratories
Astrazenca
Roche
Sanofi
Johnson &johnson
GSK
Bayer
Merck & Co
Novartis
Pfizer
Total Net revenue
Total net revenue in
USD mn
8/12/2019 HPL Pharma Ppt (1)
9/70
9
8/12/2019 HPL Pharma Ppt (1)
10/70
Evolution of Pharmaceutical Industry
10
8/12/2019 HPL Pharma Ppt (1)
11/70
Evolution of Pharmaceutical industry
Market Dominated byForeign Companieswith Little Domestic
Participation
Several DomesticCompanies Starttheir Operations
11
1970-1990
Before 1970 1990-2010
IndianCompanies
launch
operations
in foreign
countries
8/12/2019 HPL Pharma Ppt (1)
12/70
8/12/2019 HPL Pharma Ppt (1)
13/70
13
8/12/2019 HPL Pharma Ppt (1)
14/70
14
8/12/2019 HPL Pharma Ppt (1)
15/70
GROWTH
15
8/12/2019 HPL Pharma Ppt (1)
16/70
16
8/12/2019 HPL Pharma Ppt (1)
17/70
17
SWOTAnalysis
Strengths
WeaknessesOpportunities
Threats
8/12/2019 HPL Pharma Ppt (1)
18/70
18
STRENGTHS
Low cost of growingHuman resources in the
Pharmaceutical sector
Significant breadth and
depth of product expertise
Strong Low cost
manufacturing sector
8/12/2019 HPL Pharma Ppt (1)
19/70
19
WEAKNESSES
Inadequate R&D infrastructure.
Lack of time driven
regulatory infrastructure.
Poor SME base for high
end manufacture.
8/12/2019 HPL Pharma Ppt (1)
20/70
20
OPPURTUNITIES
High growth of domestic market
Low cost good skill destination
8/12/2019 HPL Pharma Ppt (1)
21/70
21
THREATS
High entry barriers.
Regulatory and non tariff
barriers.
Increased competition.
8/12/2019 HPL Pharma Ppt (1)
22/70
Market Value
Research & Development
22
FUTURE PROSPECTS
8/12/2019 HPL Pharma Ppt (1)
23/70
100 per cent FDI in Pharmaceutical sector
Jan Aushadhi Campaign
23
GOVERNMENT INITIATIVES
8/12/2019 HPL Pharma Ppt (1)
24/70
24
8/12/2019 HPL Pharma Ppt (1)
25/70
8/12/2019 HPL Pharma Ppt (1)
26/70
LUPIN PHARMACEUTICALS
26
th
8/12/2019 HPL Pharma Ppt (1)
27/70
27
8th
Largest Generics Player
Globally by Market
Capitalisation
3rd
Largest Pharmaceutical
Company in India
5th
Largest & Fastest
Growing Generics
Player in the US by
Prescription.
7thLargest Generics
Player in Japan
8/12/2019 HPL Pharma Ppt (1)
28/70
28
VALUES
INTEGRITY
WORKINGTOGETHER
RESPECT
FOR PEOPLE
CUSTOMER
ORIENTATION
ENTREPRENEURSHIP
SUPERIOR
PERFORMANCE
8/12/2019 HPL Pharma Ppt (1)
29/70
HISTORY
1968- Lupin commenced business.
1972 -Lupin Laboratories Pvt Ltd was incorporated.
1988 -(LHWRF) was founded by Dr Desh BandhuGupta.
1992 -Won FICCI's award for contribution towardsrural development.
29
8/12/2019 HPL Pharma Ppt (1)
30/70
2001 - Only Asian Pharmaceutical company to
receive US FDA approvals
2005 -Maiden Employees Stock Option Plan wasimplemented.
2011 - Lupin Acquires I'rom Pharmaceuticalsthrough its Japanese Subsidiary.
30
8/12/2019 HPL Pharma Ppt (1)
31/70
ORGANIZATIONAL STRUCTURE
31
Dr. Deshbandhu Gupta
Mrs.Vinita
GuptaMr.Nilesh
GuptaMr Shakti
ChakrabortyDr.Rajendra
KambhojMr Naresh
GuptaMr. .PaulMcGarty
Dr. KamalSharma
8/12/2019 HPL Pharma Ppt (1)
32/70
BUSINESSES
32
BUSINESS MIX
8/12/2019 HPL Pharma Ppt (1)
33/70
33
8184 85
88 90
19 16 15
12 10
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2009 2010 2011 2012 2013
BUSINESS MIX
(% CONTRIBUTION)
FORMULATION API
D ti F l ti ( Milli )
8/12/2019 HPL Pharma Ppt (1)
34/70
34
11412
13502
15734
19374
23840
0
5000
10000
15000
20000
25000
30000
2009 2010 2011 2012 2013
Domestic Formulation ( Million)
8/12/2019 HPL Pharma Ppt (1)
35/70
35
8/12/2019 HPL Pharma Ppt (1)
36/70
36
52%
22%
22%
4%
API Therapeutic Contribution
CardioVascular
Others
Anti TB
Ceps
API PRODUCTS
8/12/2019 HPL Pharma Ppt (1)
37/70
37
API PRODUCTS
8/12/2019 HPL Pharma Ppt (1)
38/70
RESEARCH & DEVELOPMENT
8/12/2019 HPL Pharma Ppt (1)
39/70
39
4119
5301
5940
7708
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
2010 2011 2012 2013
R&D spendings in Million
8/12/2019 HPL Pharma Ppt (1)
40/70
40
8/12/2019 HPL Pharma Ppt (1)
41/70
UNIQUE FEATURES
41
8/12/2019 HPL Pharma Ppt (1)
42/70
FINANCIALS
42
AWARDS & RECOGNITION
8/12/2019 HPL Pharma Ppt (1)
43/70
43
AWARDS & RECOGNITION
8/12/2019 HPL Pharma Ppt (1)
44/70
Forbes India, Business LeadershipAward,2012.
Ernst & Young Entrepreneur of the Year,2012Awarded to Ms. Vinita Gupta.
Great Place to WorkBest Companies to Workfor, 2012.
44
8/12/2019 HPL Pharma Ppt (1)
45/70
45
CORPORATE SOCIAL RESPONSIBILITY
8/12/2019 HPL Pharma Ppt (1)
46/70
8/12/2019 HPL Pharma Ppt (1)
47/70
8/12/2019 HPL Pharma Ppt (1)
48/70
ABOUT THE LEADER
Started his career teaching Chemistry at BITS,Pilani.
Established Lupin Pharmaceuticals in 1968.
Family Man.
Visionary.
48
8/12/2019 HPL Pharma Ppt (1)
49/70
49
8/12/2019 HPL Pharma Ppt (1)
50/70
50
8/12/2019 HPL Pharma Ppt (1)
51/70
51
1st WORLDS LARGEST
PHARMACEUTICAL
COMPANY
4th LARGEST PLAYER
GLOBALLY BY
MARKETCAPITALISATION
NAMED 5THBEST
WEALTH CREATOR IN
AMERICA BY FORTUNE
WORLDS LARGEST
RESEARCH BASED
PHARMACEUTICAL &
BIOMEDICAL COMPANY
8/12/2019 HPL Pharma Ppt (1)
52/70
Operates and markets its products in over 150countries worldwide.
About 98,000 employees in over 115 countries
52
ABOUT
8/12/2019 HPL Pharma Ppt (1)
53/70
53
PFIZERS CORE VALUES
Integrity Respect for People
Customer/Community Focus
Innovation
Teamwork
Performance
Leadership
Quality
COMPANY GOALS AND
8/12/2019 HPL Pharma Ppt (1)
54/70
54
COMPANY GOALS AND
OBJECTIVES
Grow in Emerging Markets.
Find new opportunities for established products.
Instill culture of innovation and continuous
improvement.
Invest in complimentary businesses.
8/12/2019 HPL Pharma Ppt (1)
55/70
55
HISTORY
Pfi I Hi t
8/12/2019 HPL Pharma Ppt (1)
56/70
56
Pfizer Inc. History
1849- Founded by Charles Pfizer and Charles Erhart in
Brooklyn,NY
1900-Incorporated in New Jersey.
1971- Companys Central Research Division created.
1995- Animal health care segment acquired from SmithKline
Beecham.
2000- Pfizer and Warner Lambert merge.
8/12/2019 HPL Pharma Ppt (1)
57/70
2003- Acquired Pharmacia Corporation, creating worlds
largest research based pharmaceutical company
2005- Acquired Vicuron Pharmaceuticals to improve
antiviral development program.
2006- Sold consumer healthcare business to J&J.
2009 -Pfizer acquires Wyeth.
2010 - Pfizer announces a diversified R&D platform
named Pfizer Worldwide Research and Development
57
ORGANISATIONAL
8/12/2019 HPL Pharma Ppt (1)
58/70
ORGANISATIONAL
STRUCTURE
58
8/12/2019 HPL Pharma Ppt (1)
59/70
BUSINESSES
59
8/12/2019 HPL Pharma Ppt (1)
60/70
GLOBAL OPPORTUNITIES
60
8/12/2019 HPL Pharma Ppt (1)
61/70
61
U.S.A : Acquiring Strong Productand Expertise .
U.K : Embedded Collaboration in Academia
8/12/2019 HPL Pharma Ppt (1)
62/70
62
FRANCE : Focused Research
Partnerships
China: Branded Generics
8/12/2019 HPL Pharma Ppt (1)
63/70
63
Japan: Branded Generics
Australia:Innovation in Sterile Injectables
FINANCIALS
8/12/2019 HPL Pharma Ppt (1)
64/70
4%4%
5%
5%
16%
32%
34%
SPECIALITY CARE
PRIMARY CARE
EMERGING MARKETS
ESTABLISHEDPRODUCTS
CONSUMERHEALTHCARE
ONCOLOGY
OTHER
BUSINESS UNIT REVENUES
64
8/12/2019 HPL Pharma Ppt (1)
65/70
65
8/12/2019 HPL Pharma Ppt (1)
66/70
RESEARCH & DEVELOPMENT
66
CORPORATE SOCIAL
8/12/2019 HPL Pharma Ppt (1)
67/70
CORPORATE SOCIAL
RESPONSIBILITY
67
LEADERSHIP AT PFIZER
8/12/2019 HPL Pharma Ppt (1)
68/70
68
LEADERSHIP AT PFIZER
8/12/2019 HPL Pharma Ppt (1)
69/70
69
8/12/2019 HPL Pharma Ppt (1)
70/70
CONCLUSION
Top Related